ReviewInternational archives of allergy and immunology2022
Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
Review in International archives of allergy and immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Mast cell activation syndrome: Global perspectives from a World Allergy Organization survey on knowledge, diagnosis, and access to care.The World Allergy Organization journal · 2026Article
- Mast cell activation syndrome-related unusual periocular inflammation associated with mydriatic eyedrops during cataract surgery.American journal of ophthalmology case reports · 2026Article
- Post-Exertional Malaise in Post-COVID-19 Syndrome: A Shift in the Frequency Across Pandemic Phases.Journal of clinical medicine · 2026Article
- Management Strategy for Anaphylaxis in a Patient With Suspected or Confirmed Mastocytosis: A Case Report.The American journal of case reports · 2026Article
- Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis.The journal of allergy and clinical immunology. In practice · 2026Review
- Mast cell activation syndromes in clinical practice: diagnostic challenges, phenotypes, and real-life management.Postepy dermatologii i alergologii · 2026Article
- The Role of Mast Cells and Their Potential as a Therapeutic Target For Neuroinflammation.Journal of inflammation research · 2026Review
- Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.American journal of hematology · 2025Review
- Article
- Diagnostic Challenges in a Young Man with a Suspected Mast Cell Disorder, Dysplastic Bone Marrow Morphology, and aHematology reports · 2025Article
- Hereditary α-Tryptasemia and Peripheral BloodInternational journal of molecular sciences · 2025Article
- IL-4, TSLP and IL-31 Cytokine Profiles as Related to Psychometric Measures in Patients with Mastocytosis.International journal of molecular sciences · 2025Article
- Spectrum, Time Course, Stages, and a Proposal for the Diagnosis of Histamine Intolerance in General Practice: A Nonrandomized, Quasi-Experimental Study.Journal of clinical medicine · 2025Article
- Dermatologic manifestations of hematologic disorders.Annals of hematology · 2024Review
- Pediatric idiopathic anaphylaxis: practical management from infants to adolescents.Italian journal of pediatrics · 2024Review
- Mast cell activation syndrome: Current understanding and research needs.The Journal of allergy and clinical immunology · 2024Review
- Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS).Vaccines · 2024Article
- Mast cell activation syndrome: An up-to-date review of literature.World journal of clinical pediatrics · 2024Review
- Bioactivity-Guided Fraction from Viscera of Abalone,Journal of microbiology and biotechnology · 2024Article
- Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mast cell activation syndromes (MCASs) are defined by systemic severe and recurrent mast cell activation, usually in form of anaphylaxis, a substantial, event-related increase of the serum tryptase level beyond the individual's baseline and a response of the symptomatology to drugs directed against mast cells, mast cell-derived mediators, or mediator effects. A number of predisposing genetic conditions, underlying allergic and other hypersensitivity states, and related comorbidities can contribute to the clinical manifestation of MCASs. These conditions include hereditary alpha tryptasemia, mastocytosis with an expansion of clonal KIT-mutated mast cells, atopic diathesis, and overt IgE-dependent and IgE-independent allergies. Several of these conditions have overlapping definitions and diagnostic criteria and may also develop concomitantly in the same patient. However, although criteria and clinical features overlap, each of these conditions is characterized by a unique constellation of variables and diagnostic criteria. Since two, three, or more conditions can coexist in the same patient, with obvious clinical implications, it is of crucial importance to diagnose the variant of MCAS precisely and to take all accompanying, underlying and potentially complicating conditions, and comorbidities into account when establishing the management plan. Indeed, most of these patients require multidisciplinary investigations and only a personalized treatment approach can lead to an optimal management plan providing an optimal quality of life and low risk of anaphylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.